Elyse G. Schechter

Elyse G. Schechter

Auto-generated profile, based on publicly available information

Elyse G. Schechter

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Cancer Research
Verified
Journal Article
Closed access
JDJonathan M. DeLiberty
Jonathan M. DeLiberty
MRMallory K. Roach
Mallory K. Roach
CSClint A. Stalnecker
Clint A. Stalnecker
RRRyan Robb
Ryan Robb
ESElyse G. Schechter
Elyse G. Schechter
KBKirsten L. Bryant
Kirsten L. Bryant
Pancreatic ductal adenocarcinoma (PDAC) is characterized by KRAS- and autophagy-dependent growth. Inhibition of the KRAS–RAF–MEK–ERK pathway enhances autophagic flux and dependency, and concurrent treatment with the nonspecific autophagy inhibitor chloroquine (CQ) and ERK–MAPK pathway inhibitors can synergistically block PDAC growth. However, CQ is limited in terms of specificity and potency. To find alternative anti-autophagy strategies, in this study, we performed a CRISPR-Cas9 loss-of-function screen in PDAC cell lines that identified the lipid kinase phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as a growth-promoting gene. PIKfyve inhibition by the small molecule apilimod resulted in durable growth suppression, with much greater potency than CQ treatment. PIKfyve inhibition caused lysosomal dysfunction, reduced autophagic flux, and led to the accumulation of autophagy-related proteins. Furthermore, PIKfyve inhibition blocked the compensatory increases in autophagic flux associated both with MEK inhibition and with direct RAS inhibition. Accordingly, combined inhibition of PIKfyve and the RAS–MAPK pathway showed robust growth suppression across a panel of KRAS-mutant PDAC models. Growth suppression was due, in part, to potentiated cell-cycle arrest and induction of apoptosis following loss of inhibitor of apoptosis proteins. These findings indicate that concurrent inhibition of RAS and PIKfyve is a synergistic, cytotoxic combination that may represent a therapeutic strategy for PDAC. Significance: PIKfyve inhibition effectively blocks autophagy in multiple models of KRAS-mutant pancreatic cancer and can synergize with inhibitors of members of the RAS–MAPK pathway, providing an effective combination strategy for pancreatic cancer.

13 May 2025
Verified
Other
Open access
PDF file
JDJonathan M. DeLiberty
Jonathan M. DeLiberty
MRMallory K. Roach
Mallory K. Roach
CSClint A. Stalnecker
Clint A. Stalnecker
RRRyan Robb
Ryan Robb
ESElyse G. Schechter
Elyse G. Schechter
KBKirsten L. Bryant
Kirsten L. Bryant
Identification of PIKfyve as a potential anti-autophagy target in PDAC

13 May 2025
Verified
Other
Open access
PDF file
JDJonathan M. DeLiberty
Jonathan M. DeLiberty
MRMallory K. Roach
Mallory K. Roach
CSClint A. Stalnecker
Clint A. Stalnecker
RRRyan Robb
Ryan Robb
ESElyse G. Schechter
Elyse G. Schechter
KBKirsten L. Bryant
Kirsten L. Bryant
RAS ERK-MAPK pathway inhibition induces autophagic flux and synergizes with PIKfyvei to impair proliferation of PDAC cell lines

13 May 2025
Verified
Other
Open access
PDF file
JDJonathan M. DeLiberty
Jonathan M. DeLiberty
MRMallory K. Roach
Mallory K. Roach
CSClint A. Stalnecker
Clint A. Stalnecker
RRRyan Robb
Ryan Robb
ESElyse G. Schechter
Elyse G. Schechter
KBKirsten L. Bryant
Kirsten L. Bryant
The PIKfyve inhibitor apilimod impairs autophagic flux in PDAC cells

17 June 2026
Verified
Other
Open access
PDF file
JDJonathan M. DeLiberty
Jonathan M. DeLiberty
MRMallory K. Roach
Mallory K. Roach
CSClint A. Stalnecker
Clint A. Stalnecker
RRRyan Robb
Ryan Robb
ESElyse G. Schechter
Elyse G. Schechter
KBKirsten L. Bryant
Kirsten L. Bryant
Combined inhibition of PIKfyve and the RAS ERK-MAPK pathway induces apoptosis in PDAC cell lines

17 June 2026
Verified
Other
Open access
PDF file
JDJonathan M. DeLiberty
Jonathan M. DeLiberty
MRMallory K. Roach
Mallory K. Roach
CSClint A. Stalnecker
Clint A. Stalnecker
RRRyan Robb
Ryan Robb
ESElyse G. Schechter
Elyse G. Schechter
KBKirsten L. Bryant
Kirsten L. Bryant
Identification of PIKfyve as a potential anti-autophagy target in PDAC